Latest news with #AdiaNutrition
Globe and Mail
06-08-2025
- Health
- Globe and Mail
Adia Nutrition Inc. Celebrates Adia Med's Approval as a UnitedHealthcare Provider in $5.3 Trillion Healthcare Market
Winter Park, Florida--(Newsfile Corp. - August 6, 2025) - Adia Nutrition Inc. (OTCQB: ADIA) is proud to announce that its healthcare clinic, Adia Med, has been officially approved as a provider with UnitedHealthcare, effective as of August 1, 2025. This significant milestone positions Adia Med within the $5.3 trillion U.S. healthcare market [CMS National Health Expenditure Projections, 2024-2033], enabling the clinic to expand access to its innovative regenerative medicine treatments for orthopedic injuries, chronic pain, and wound repair to millions of UnitedHealthcare members. UnitedHealthcare Logo Cannot view this image? Visit: Adia Med's integration into UnitedHealthcare's expansive network enhances its ability to deliver cutting-edge, minimally invasive therapies that promote faster recovery with minimal downtime, addressing conditions such as joint pain, sports injuries, and chronic wounds. This approval underscores Adia Nutrition's commitment to transforming patient care through regenerative solutions, ensuring patients can resume their active lifestyles efficiently and effectively. "We are thrilled to join UnitedHealthcare's vast provider network, a pivotal step in bringing our regenerative treatments to a broader audience in this $5.3 trillion market," said Larry Powalisz, CEO at Adia Nutrition Inc. "Adia Med is dedicated to helping patients overcome chronic conditions while supporting other clinics in expanding their regenerative medicine offerings." Located in Winter Park, Florida, Adia Med is staffed by experienced physicians and autonomous Advanced Practice Registered Nurses (APRNs) who provide personalized, patient-centered care. The clinic leverages the latest advancements in regenerative medicine to address complex conditions, ensuring high-quality outcomes. For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@ or by phone at 321-788-0850. Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions. About ADIA Nutrition Inc.: Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: Website: Website: Website: Twitter (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
Yahoo
14-07-2025
- Business
- Yahoo
Adia Nutrition Inc. Celebrates Grand Opening of Adia Med of San Antonio, First Licensed Clinic, Led by Michele DeLeon MD
Winter Park, Florida--(Newsfile Corp. - July 14, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine, proudly announces the grand opening of Adia Med of San Antonio, its first licensed clinic under a strategic license agreement, located at 18707 Hardy Oak Blvd, Suite 500, San Antonio, Texas 78258. Headed by esteemed wellness regenerative expert Michele DeLeon MD, this cutting-edge facility marks a significant step in expanding access to innovative regenerative therapies across the United States. Adia Med of San Antonio will offer FDA-registered products, including AdiaVita The Most Trusted Brand (umbilical cord stem cells with 100 million viable cells and 3 trillion exosomes per unit) and AdiaLink (3.5 trillion exosomes per unit). Additionally, Adia Med of San Antonio will collaborate with Adia Med of Winter Park in a groundbreaking clinical study exploring regenerative therapies for autism, further advancing the company's commitment to transformative healthcare solutions. "We are thrilled to launch Adia Med of San Antonio as our first licensed clinic, under the exceptional leadership of Michele DeLeon MD," said Larry Powalisz, CEO of Adia Nutrition Inc. "This vibrant new location, combined with clinical study for autism alongside Adia Med of Winter Park, is a testament to our unwavering commitment to transforming lives through cutting-edge care. San Antonio is just the beginning of an exciting new chapter for Adia Nutrition." "Equipped with state-of-the-art technology and staffed by a highly trained team, Adia Med of San Antonio upholds the rigorous standards of Adia Nutrition's existing clinics, including Adia Med Winter Park. For those interested in licensing Adia Med's name and becoming part of its innovative network, please reach out to ceo@ or call 321-788-0850 for more information. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit
Yahoo
02-07-2025
- Business
- Yahoo
Adia Nutrition Inc. Advances Toward United Healthcare Provider Approval for Adia Med Services, Signaling Major Growth Opportunity
Winter Park, Florida--(Newsfile Corp. - July 2, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded leader in advanced regenerative therapies, is pleased to announce that its medical subsidiary, Adia Med, is in the final stages of approval to become an in-network provider with United Healthcare, one of the largest and most influential health insurance companies in the U.S. The company anticipates final approval by August 1, 2025, which will significantly expand Adia Med's market reach by making its cutting-edge medical services eligible for reimbursement under United Healthcare policies. United Healthcare To view an enhanced version of this graphic, please visit: This strategic milestone positions Adia Nutrition to tap into a vastly larger patient population while driving new revenue streams from insurance-backed procedures such as Autologous Hematopoietic Stem Cell Transplantation (AHSCT), Therapeutic Plasma Exchange (TPE), and stem cell therapies that may be covered under the patient's insurance. "This anticipated provider agreement with United Healthcare is a pivotal step forward in our growth trajectory," said Larry Powalisz, CEO of Adia Nutrition Inc. "It enables Adia Med to deliver its advanced, high-demand therapies to a broader population with insurance support, opening the door for accelerated patient acquisition and scalable expansion." Once approved, Adia Med will join a select network of providers meeting United Healthcare's rigorous standards for clinical excellence, compliance, and patient care. The company has already begun submitting its first patient's insurance claim through UnitedHealthcare-a strong signal of imminent integration. United Healthcare's partnership not only validates the clinical quality of Adia Med's offerings but also provides a scalable reimbursement pathway for advanced treatments in the fast-growing regenerative medicine sector. For investor inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.: Adia Nutrition Inc. (OTCQB: ADIA) is a publicly traded company dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events, or otherwise. To view the source version of this press release, please visit Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
Globe and Mail
19-06-2025
- Business
- Globe and Mail
Timing Is Everything - Adia Nutrition Inc. Celebrates Florida's SB 1768 with Open Invitations to Adia Med Clinic
Winter Park, Florida--(Newsfile Corp. - June 19, 2025) - Adia Nutrition Inc., (OTCQB: ADIA) a rising leader in the $15.1 billion global stem cell industry, enthusiastically welcomes Florida's Senate Bill 1768. Signed into law last month and effective July 1, 2025, this transformative legislation permits physicians to offer stem cell therapies for orthopedics, wound repair, and pain management, expanding access to cutting-edge treatments while maintaining rigorous safety standards. Florida's SB 1768 To view an enhanced version of this graphic, please visit: SB 1768 authorizes medical and osteopathic doctors to perform, ensuring high-quality patient care through strict safety and efficacy requirements. This milestone establishes Florida as a frontrunner in regenerative medicine, responding to growing patient demand for innovative treatment options. Adia Nutrition Inc., through its Adia Med clinic in Winter Park, is eager to support this groundbreaking change. The company is collaborating with clinics across Florida, offering comprehensive assistance to navigate the new law. Adia provides unmatched support for stem cell trials, research, and procedures, enabling clinics to seamlessly integrate these therapies. Committed to excellence, Adia delivers industry-leading customer service and relationship management to foster strong partnerships that enhance patient outcomes. Starting July 1, 2025, Adia Med of Winter Park will mail invitations to celebrate the passage of SB 1768, inviting the community to visit the clinic and explore its advanced regenerative therapies. For a limited time, Adia Med will offer free consultations to showcase its state-of-the-art facilities and personalized care. "We're thrilled about SB 1768 and its impact on patient care," said Larry Powalisz, CEO of Adia Nutrition Inc. "Our team is dedicated to helping clinics implement stem cell therapies with top-tier support and service. I personally invite everyone-whether you're in Florida or anywhere across the country-to visit Adia Med in Winter Park for world-class treatment and to experience the future of regenerative medicine." Clinics interested in adopting stem cell therapies are encouraged to contact Adia Nutrition Inc. for expert guidance. By partnering with Adia, clinics gain access to premium stem cell and exosome products backed by Adia's exceptional expertise. For more information, to explore partnership opportunities, or to schedule a visit to Adia Med, contact Adia Nutrition Inc. at ceo@ or 321-788-0850, or visit Adia remains dedicated to advancing healthcare through innovative stem cell solutions and meaningful collaborations. THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW. This health care practitioner performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.: Adia Nutrition Inc. (OTCQB: ADIA) is a publicly traded company dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
Yahoo
16-06-2025
- Health
- Yahoo
Home Run! Adia Med of Winter Park's AHCA Triumph Brings Insurance-Covered Healing to Patients
Winter Park, Florida--(Newsfile Corp. - June 16, 2025) - Adia Nutrition, Inc. (OTCQB: ADIA), a leading innovator in regenerative medicine and nutritional supplements, is thrilled to announce that its state-of-the-art clinic, Adia Med of Winter Park, has received full approval from the Agency for Health Care Administration (AHCA). This milestone allows Adia Med of Winter Park to accept insurance, marking a significant advancement in providing accessible, life-changing treatments to patients across Florida. To view an enhanced version of this graphic, please visit: The AHCA approval positions Adia Med of Winter Park as a premier destination for innovative therapies, including Autologous Hematopoietic Stem Cell Transplantation (aHSCT) for Multiple Sclerosis (MS) and other autoimmune conditions, as well as therapeutic plasma exchange (TPE), and other breakthrough medical treatments. By accepting insurance, Adia Nutrition can now work directly with patients to advocate for coverage, making transformative treatments more affordable and accessible. "This AHCA approval is a game-changer for Adia Nutrition and our patients," said Larry Powalisz, Chief Executive Officer of Adia Nutrition. "Being able to accept insurance means we can partner with patients to fight for their right to coverage for innovative therapies like aHSCT, which have the potential to dramatically improve quality of life. We're committed to breaking down financial barriers and delivering world-class care." Located in Winter Park, Florida, Adia Med of Winter Park, which opened in January 2025, is equipped to deliver cutting-edge regenerative treatments tailored to individual patient needs. The clinic's approval by AHCA underscores its compliance with Florida's rigorous healthcare standards, reinforcing Adia Nutrition's entry in the $4.9 trillion health-care insurance market. Historical | CMS Patients interested in exploring insurance-covered treatment options at Adia Med of Winter Park are encouraged to fill out the contact form at For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
